Harnessing the power of your immune system to fight cancer—personalised, innovative, and life-changing treatment.
More than 100+ Hospital collaborated with us
Target group: Children and young adults
ALL is a fast-growing cancer that starts in immature white blood cells in the bone marrow. CAR T-cell therapy has shown high remission rates in patients who have relapsed after chemotherapy or bone marrow transplant.
Target group: Children and young adults
DLBCL is the most common subtype of non-Hodgkin lymphoma. It can grow quickly and become resistant to standard treatments. CAR T-cell therapy is now a standard of care for relapsed or refractory DLBCL after two or more lines of therapy.
Target group: Adults over 18
DLBCL is the most common subtype of non-Hodgkin lymphoma. It can grow quickly and become resistant to standard treatments. CAR T-cell therapy is now a standard of care for relapsed or refractory DLBCL after two or more lines of therapy.
Target group: Children and young adults
This cancer affects plasma cells in the bone marrow. Patients with advanced stages often run out of treatment options. CAR T-cell therapy for multiple myeloma (targeting BCMA protein) has shown promising results in extending survival.
“Joining this platform was the best decision I’ve made for my career. The digital marketing strategies I learned have boosted my company’s growth.”
Dr. Alex Mindayanthi
Car T-Cell is a growing therapy working towards changing the way individual think
Hearing from survivors is one of the most powerful ways to understand the impact of CAR T-cell ther Read More…
06 April, 2025
Not everyone is a candidate for CAR T-cell therapy. This article walks you through eligibility criteria, Read More…
06 April, 2025
Our team of top oncologists and researchers specialises, offering personalised cancer care.
We partner with top hospitals
across India, ensuring safe and effective CAR T-cell therapy with expert care.
We prioritize patient well-being, offering full support from consultation to post-treatment care.
Harnessing the power of your immune system to fight cancer—personalized, innovative, and life-changing treatment.
People with certain blood cancers (like leukemia, lymphoma, myeloma) that did not improve with other treatments.
Doctors take your T-cells, reprogram them in a lab, and put them back so they can find and kill cancer cells.
Fever, tiredness, confusion, or low blood pressure. Most side effects happen in the first few days and can be treated.
Usually 3–6 weeks from collecting the cells to giving the CAR T infusion.
Many patients show strong response, even when other treatments failed—some go into long-term remission.
© 2025 CAR T-Shell Therapy. All rights reserved.
Harnessing the power of your immune system to fight cancer—personalized, innovative, and life-changing treatment.
